Compare TGLS & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGLS | ANIP |
|---|---|---|
| Founded | 1984 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2011 | 1999 |
| Metric | TGLS | ANIP |
|---|---|---|
| Price | $42.98 | $86.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $63.33 | ★ $110.00 |
| AVG Volume (30 Days) | 269.5K | ★ 293.5K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | 0.71 | ★ 1.28 |
| Revenue | ★ $370,984,000.00 | $206,547,000.00 |
| Revenue This Year | $13.56 | $21.01 |
| Revenue Next Year | $9.04 | $17.59 |
| P/E Ratio | ★ $60.92 | $67.18 |
| Revenue Growth | ★ 17.98 | 2.47 |
| 52 Week Low | $37.52 | $62.61 |
| 52 Week High | $83.32 | $99.50 |
| Indicator | TGLS | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 61.80 |
| Support Level | $40.57 | $77.16 |
| Resistance Level | $46.65 | $87.42 |
| Average True Range (ATR) | 1.90 | 2.60 |
| MACD | -0.19 | 0.34 |
| Stochastic Oscillator | 9.43 | 86.39 |
Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.